Asep Medical Holdings Inc C.ASEP

AI-driven Sepsis Tech could be groundbreaking

[waves1]

Solid news from ASEP Medical ($ASEP.c) earlier this month, announcing that it has finalized an exclusive licensing arrangement with UBC for a patented and potentially groundbreaking AI-driven sepsis technology!

Developed under the direction of leading UBC microbiologist and ASEP's Founding Director and COO, Dr. Robert E.W. Hancock, the tech enables early and accurate diagnosis of sepsis.

$ASEP's novel diagnostic test, called Sepset, senses the dysfunctional immune response underlying sepsis and it is a blood-based gene expression assay that is straightforward to implement, and results are obtained in about an hour. Sepset enables quick predictions of the severity of the disease to define better and more immediate treatment options for the patient.

Dr. Robert E.W. Hancock added, "This technology will enable us to make a major impact on the lives of patients who acquire this deadly syndrome. Early and accurate diagnosis is vital to saving lives and we expect this technology to be widely used in hospitals and clinics around the world."

$ASEP is now making plans to initiate clinical studies to support a regulatory filing for commercial approval later in the year. 2022 seems to be shaping up to be a promising year for $ASEP, I'm looking forward to what comes next

https://www.newswire.ca/news-releases/asep-medical-holdings-inc-announces-an-exclusive-licensing-arrangement-for-a-patented-and-novel-ai-driven-sepsis-diagnosis-technology-developed-at-the-university-of-british-columbia-ubc--825261856.html